Asthma endotypes and COVID-19

Alberca, Ricardo Wesley

doi:10.1080/02770903.2020.1825731

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High serum levels of MCP-1 are inversely related to the platelets count. Alberca et al, 2021 [13] agreed with our results and claimed that platelets are destroyed during the process of production of cytokines and chemokines. He added that recently the platelet count has been proposed as a severity biomarker in COVID-19, and thrombocytopenia at the first day of hospitalization has been proposed as a biomarker for a higher mortality rate.…”

Section: Carr Et Al 1994supporting

confidence: 91%

Correlation Between Monocytic Chemotactic Protein-1 (Mcp-1) and the Severity of Covid-19 Infection.

2022

Ain Shams Medical Journal

View full text Add to dashboard Cite

Background:The ongoing pandemic of coronavirus disease 2019 poses several challenges to clinicians. Serum chemokine levels such as MCP-1and IL-6 are elevated in patients with COVID-19, and they are even higher in those who required intensivecare unit (ICU) admission, suggesting a relationship between these chemokines and both lung damage and disease severity. Aim of the study:To evaluate the level of monocytic chemotactic protein-1 (MCP-1) in mild, severe and post COVID-19 patients to explore the correlation between (MCP-1) and the severity of the disease. The findings of this study will add to our understanding the role of MCP-1 in diagnosis of COVID-19 patients and the relation between MCP-1 level and the severity of the disease, providing potential diagnostic, prognostic and even therapeutic strategies for COVID-19 patients using MCP-1 as a marker.

show abstract

Section: Carr Et Al 1994supporting

confidence: 91%

Correlation Between Monocytic Chemotactic Protein-1 (Mcp-1) and the Severity of Covid-19 Infection.

2022

Ain Shams Medical Journal

View full text Add to dashboard Cite

show abstract

“…The infection caused by SARS-CoV-2 can lead to the development of a severe pulmonary and systemic disease named COVID-19 (Alberca et al, 2020c). Previous reports have identified that COVID-19 is often more severe in the elderly and individuals with comorbidities such as obesity, hypertension, diabetes Mellitus, other co-infections (Alberca, 2020;Alberca et al, 2020a,d,f;Castelo Branco et al, 2020;Shaw et al, 2020). Those patients generally present an increase in COVID-19associated inflammatory markers, such as d-dimer, leukocytes count, neutrophil count, neutrophil-to-lymphocyte (NTL) ratio, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and c-reactive protein (CRP) (Wolff et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

The severe respiratory and systemic disease named coronavirus disease-2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, the COVID-19 pandemic presents a huge social and health challenge worldwide. Many different risk factors are associated with disease severity, such as systemic arterial hypertension, diabetes mellitus, obesity, older age, and other co-infections. Other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and smoking are common comorbidities worldwide. Previous investigations have identified among COVID-19 patients smokers and COPD patients, but recent investigations have questioned the higher risk among these populations. Nevertheless, previous reports failed to isolate smokers and COPD patients without other comorbidities. We performed a longitudinal evaluation of the disease course of smokers, former smokers, and COPD patients with COVID-19 without other comorbidities, from hospitalization to hospital discharge. Although no difference between groups was observed during hospital admission, smokers and COPD patients presented an increase in COVID-19-associated inflammatory markers during the disease course in comparison to non-smokers and former smokers. Our results demonstrated that smoking and COPD are risk factors for severe COVID-19 with possible implications for the ongoing pandemic.

show abstract

“…And asthma is associated with a reduction in the severity of COVID-19 [121,122]. It is important to highlight that non-allergic asthma or neutrophilic asthma increases the production of IL-17 in the lungs, which increases ACE2 expression, therefore possibly increasing the risk for severe COVID-19 [123].…”

Section: Chronic Obstructive Pulmonary Disease (Copd) Smoking and Other Respiratory Disordersmentioning

confidence: 99%

Immune Response to COVID-19

Alberca¹

2021

Fighting the COVID-19 Pandemic

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invades the host’s cells via the angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). ACE2 and TMPRSS2 molecules are highly expressed on the respiratory tract but are also expressed in other organs such as kidneys, heart, and intestine, which could partially explain the multiple organ infection, damage, and failure. During the COVID-19 disease course, patients may develop a dysregulation in the immune response, with an exacerbated production of pro-inflammatory molecules and hypercoagulation, which can collaborate to the increase in tissue damage and death. This chapter will cover general aspects of the innate and adaptive immune response during COVID-19, the impact of comorbidities on the immune response to SARS-CoV-2, and the immune response generated by COVID-19 vaccines.

show abstract

Asthma endotypes and COVID-19

Cited by 3 publications

References 22 publications

Correlation Between Monocytic Chemotactic Protein-1 (Mcp-1) and the Severity of Covid-19 Infection.

Correlation Between Monocytic Chemotactic Protein-1 (Mcp-1) and the Severity of Covid-19 Infection.

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

Immune Response to COVID-19

Contact Info

Product

Resources

About